WO2013040471A3 - Noribogaine salt ansolvates - Google Patents

Noribogaine salt ansolvates Download PDF

Info

Publication number
WO2013040471A3
WO2013040471A3 PCT/US2012/055597 US2012055597W WO2013040471A3 WO 2013040471 A3 WO2013040471 A3 WO 2013040471A3 US 2012055597 W US2012055597 W US 2012055597W WO 2013040471 A3 WO2013040471 A3 WO 2013040471A3
Authority
WO
WIPO (PCT)
Prior art keywords
ansolvates
noribogaine
noribogaine salt
solvated
salt ansolvates
Prior art date
Application number
PCT/US2012/055597
Other languages
French (fr)
Other versions
WO2013040471A2 (en
Inventor
Richard D. Gless
William C. Schinzer
Original Assignee
Demerx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47881233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2013040471(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN201280039971.6A priority Critical patent/CN103857397B/en
Priority to NZ620948A priority patent/NZ620948B2/en
Priority to SG2014011811A priority patent/SG2014011811A/en
Priority to BR112014005064A priority patent/BR112014005064A2/en
Priority to EP12832208.8A priority patent/EP2755658A4/en
Priority to KR1020147004777A priority patent/KR20140062472A/en
Priority to MX2014001933A priority patent/MX2014001933A/en
Priority to KR1020207027537A priority patent/KR102381792B1/en
Priority to RU2014105881/04A priority patent/RU2014105881A/en
Priority to AU2012308274A priority patent/AU2012308274B2/en
Application filed by Demerx, Inc. filed Critical Demerx, Inc.
Priority to CA2845007A priority patent/CA2845007C/en
Publication of WO2013040471A2 publication Critical patent/WO2013040471A2/en
Publication of WO2013040471A3 publication Critical patent/WO2013040471A3/en
Priority to IL230940A priority patent/IL230940B/en
Priority to ZA2014/01268A priority patent/ZA201401268B/en
Priority to HK15100394.5A priority patent/HK1199840A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water.
PCT/US2012/055597 2011-09-15 2012-09-14 Noribogaine salt ansolvates WO2013040471A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA2845007A CA2845007C (en) 2011-09-15 2012-09-14 Ansolvate or crystalline polymorph noribogaine salts
AU2012308274A AU2012308274B2 (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates
RU2014105881/04A RU2014105881A (en) 2011-09-15 2012-09-14 NORIBOGAIN SALTS ANSOLVATES
BR112014005064A BR112014005064A2 (en) 2011-09-15 2012-09-14 norigobaain salt non-solvates
NZ620948A NZ620948B2 (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates
KR1020147004777A KR20140062472A (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates
MX2014001933A MX2014001933A (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates.
CN201280039971.6A CN103857397B (en) 2011-09-15 2012-09-14 Noribogaine salt non-solvent compound
SG2014011811A SG2014011811A (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates
EP12832208.8A EP2755658A4 (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates
KR1020207027537A KR102381792B1 (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates
IL230940A IL230940B (en) 2011-09-15 2014-02-12 Noribogaine salt ansolvates
ZA2014/01268A ZA201401268B (en) 2011-09-15 2014-02-19 Noribogaine salt ansolvates
HK15100394.5A HK1199840A1 (en) 2011-09-15 2015-01-14 Noribogaine salt ansolvates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535300P 2011-09-15 2011-09-15
US61/535,300 2011-09-15

Publications (2)

Publication Number Publication Date
WO2013040471A2 WO2013040471A2 (en) 2013-03-21
WO2013040471A3 true WO2013040471A3 (en) 2013-05-10

Family

ID=47881233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/055597 WO2013040471A2 (en) 2011-09-15 2012-09-14 Noribogaine salt ansolvates

Country Status (18)

Country Link
US (4) US9040520B2 (en)
EP (1) EP2755658A4 (en)
KR (2) KR20140062472A (en)
CN (2) CN105949193A (en)
AU (1) AU2012308274B2 (en)
BR (1) BR112014005064A2 (en)
CA (1) CA2845007C (en)
CL (1) CL2014000506A1 (en)
CO (1) CO6970589A2 (en)
HK (1) HK1199840A1 (en)
IL (1) IL230940B (en)
MX (1) MX2014001933A (en)
PE (1) PE20142353A1 (en)
RU (1) RU2014105881A (en)
SG (1) SG2014011811A (en)
TW (2) TW201726676A (en)
WO (1) WO2013040471A2 (en)
ZA (1) ZA201401268B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394294B2 (en) * 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) * 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
RU2586296C2 (en) 2010-07-23 2016-06-10 Демеркс, Инк. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2845007C (en) 2011-09-15 2020-09-29 Demerx, Inc. Ansolvate or crystalline polymorph noribogaine salts
EP2788003A4 (en) 2011-12-09 2015-05-27 Demerx Inc Phosphate esters of noribogaine
PE20221914A1 (en) 2011-12-28 2022-12-23 Global Blood Therapeutics Inc SUBSTITUTE BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2807168A4 (en) 2012-01-25 2015-10-14 Demerx Inc Synthetic voacangine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR101971385B1 (en) 2013-03-15 2019-04-22 글로벌 블러드 테라퓨틱스, 인크. Compounds and uses thereof for the modulation of hemoglobin
CA2942638A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
CN112500338A (en) 2013-03-15 2021-03-16 全球血液疗法股份有限公司 Compounds and their use for modulating hemoglobin
AU2014237330A1 (en) 2013-03-15 2015-09-17 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
AU2015214182B2 (en) * 2014-02-07 2020-04-30 Global Blood Therapeutics, Inc. Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
EA201691647A1 (en) 2014-02-18 2017-01-30 Демеркс, Инк. METHODS OF SHORT-TERM AND LONG-TERM TREATMENT OF DEPENDENCE ON DRUGS
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
EP3845275A1 (en) 2014-11-26 2021-07-07 DemeRx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
MA43373A (en) 2015-12-04 2018-10-10 Global Blood Therapeutics Inc DOSAGE REGIMES FOR 2-HYDROXY-6 - ((2- (1-ISOPROPYL-1H-PYRAZOL-5-YL) PYRIDIN-3-YL) METHOXY) BENZALDEHYDE
TWI663160B (en) 2016-05-12 2019-06-21 全球血液治療公司 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2020072377A1 (en) 2018-10-01 2020-04-09 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
AU2020259406A1 (en) 2019-04-17 2021-11-04 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591738A (en) * 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US6348456B1 (en) * 1994-07-25 2002-02-19 Deborah C. Mash Method of treating chemical dependency in mammals and a composition therefor
US20040102638A1 (en) * 2002-11-08 2004-05-27 Russell Brenton William Polymorphs of bicifadine hydrochloride
US20090186878A1 (en) * 2006-01-31 2009-07-23 Thallion Pharmaceuticals Inc. Crystalline forms of a farnesyl dibenzodiazepinone
US20100311725A1 (en) * 1997-09-04 2010-12-09 Demerx, Inc. Noribogaine in the treatment of pain and drug addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2813873A (en) * 1957-11-19 Derivatives of the ibogaine alkaloids
GB789870A (en) 1955-10-10 1958-01-29 Gobey Lab Alkaloid derivatives
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
RU2586296C2 (en) * 2010-07-23 2016-06-10 Демеркс, Инк. Noribogaine compositions
EP2481740B1 (en) * 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
CA2845007C (en) 2011-09-15 2020-09-29 Demerx, Inc. Ansolvate or crystalline polymorph noribogaine salts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348456B1 (en) * 1994-07-25 2002-02-19 Deborah C. Mash Method of treating chemical dependency in mammals and a composition therefor
US5591738A (en) * 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
US20100311725A1 (en) * 1997-09-04 2010-12-09 Demerx, Inc. Noribogaine in the treatment of pain and drug addiction
US20040102638A1 (en) * 2002-11-08 2004-05-27 Russell Brenton William Polymorphs of bicifadine hydrochloride
US20090186878A1 (en) * 2006-01-31 2009-07-23 Thallion Pharmaceuticals Inc. Crystalline forms of a farnesyl dibenzodiazepinone

Also Published As

Publication number Publication date
CN103857397B (en) 2016-08-17
AU2012308274B2 (en) 2017-08-17
KR20140062472A (en) 2014-05-23
HK1199840A1 (en) 2015-07-24
US9617265B2 (en) 2017-04-11
MX2014001933A (en) 2014-03-27
EP2755658A2 (en) 2014-07-23
BR112014005064A2 (en) 2017-04-04
CL2014000506A1 (en) 2014-08-22
TWI588145B (en) 2017-06-21
KR20200115661A (en) 2020-10-07
AU2012308274A1 (en) 2014-02-27
TW201313720A (en) 2013-04-01
EP2755658A4 (en) 2015-03-18
US9040520B2 (en) 2015-05-26
CN103857397A (en) 2014-06-11
CN105949193A (en) 2016-09-21
US20130072472A1 (en) 2013-03-21
US20170022194A1 (en) 2017-01-26
WO2013040471A2 (en) 2013-03-21
NZ620948A (en) 2016-10-28
CO6970589A2 (en) 2014-06-13
KR102381792B1 (en) 2022-04-01
CA2845007C (en) 2020-09-29
RU2014105881A (en) 2015-10-20
SG2014011811A (en) 2014-05-29
IL230940A0 (en) 2014-03-31
TW201726676A (en) 2017-08-01
ZA201401268B (en) 2016-11-30
CA2845007A1 (en) 2013-03-21
IL230940B (en) 2022-04-01
PE20142353A1 (en) 2015-01-10
US20170022193A1 (en) 2017-01-26
US20160108043A1 (en) 2016-04-21

Similar Documents

Publication Publication Date Title
WO2013040471A3 (en) Noribogaine salt ansolvates
HK1246783A1 (en) Pyridazine derivatives useful in therapy
EP2691096B8 (en) Pouch containing nicotine in free salt form
PL2756763T3 (en) Sweetener composition for alleviating diabetes, containing slowly digestible ingredient
EP2770916A4 (en) Surgically closing percutaneously punctures
EP2746283A4 (en) Pyrimidopyrimidone derivatives, pharmaceutical compositions and uses thereof
HK1162498A1 (en) Tosylate salt of a 5-pyrazolyl-2-pyridone derivative, useful in the treatment of copd copd 5--2-
IL223844A (en) Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
IL215399A (en) Methods for preparing pharmaceutical agents
WO2012103028A3 (en) Methods and compositions for preparing noribogaine from voacangine
ZA201201349B (en) Dihydropteridinone derivatives, preparation process amd pharmaceutical use thereof
WO2012135047A3 (en) Methods and compositions for preparing noribogaine from voacangine
SG11201401138RA (en) Ion exchange compositions, methods for making and materials prepared therefrom
EP2676556A4 (en) Method for manufacturing ingredient for tea drink
EP2562172A4 (en) Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses
MX359825B (en) Pyrazole compound and use thereof for medical purposes.
IL231383A (en) Imdiazole amine derivatives, their preparation and pharmaceutical compositions containing them
PL2526828T3 (en) Joint fitting, in particular for furniture
IL231699A (en) Benzyl piperidine derivatives, their preparation and pharmaceutical compositions containing them
EP2716640A4 (en) Hexahydrodibenzo[a,g]quinolizine compound, preparation method therefor, pharmaceutical composition and use thereof
EP2609933A4 (en) Aqueous composition for ophthalmic administration
EP2742946A4 (en) Method for producing pyrostegia venusta derivatives, pyrostegia venusta derivatives, pharmaceutical compositions and uses thereof
ZA201306419B (en) Compositions and methods for separating,characterizing and administering soluble selenoglycoproteins
EP2738176A4 (en) Water soluble camptothecin derivative, pharmaceutical composition and use thereof
EP2725024A4 (en) Azole heterocyclic compound, preparation method, pharmaceutical composition and use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12832208

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2845007

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 230940

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2014/001933

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20147004777

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012308274

Country of ref document: AU

Date of ref document: 20120914

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012832208

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014000506

Country of ref document: CL

WWE Wipo information: entry into national phase

Ref document number: 000301-2014

Country of ref document: PE

WWE Wipo information: entry into national phase

Ref document number: A201401467

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 12014500589

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15294174

Country of ref document: CO

Ref document number: 14057046

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2014105881

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014005064

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014005064

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140305